Lumicell

Lumicell is a pioneering oncology surgery company that has achieved a significant milestone with FDA approval of its integrated drug-device system for real-time detection of residual breast cancer during lumpectomy. The company's technology platform utilizes a fluorescent imaging agent and a handheld probe to help surgeons identify and excise cancerous tissue that would otherwise be left behind, potentially reducing re-operation rates and improving patient outcomes. With its first product commercially launched in the U.S., Lumicell is now executing its go-to-market strategy while exploring expansion into other solid tumor indications like gastrointestinal cancers. The company is privately held and based in Needham, Massachusetts.

Integrated drug-device fluorescence-guided imaging system. Comprises LUMISIGHT™ (pegulicianine), an IV-administered fluorescent imaging agent taken up by cancer cells, and the Lumicell™ Direct Visualization System (DVS), a handheld probe that illuminates and detects residual fluorescent cancer cells in real-time during surgery.

Lumicell competes in the intraoperative imaging and margin assessment market. Competitors include other fluorescence-guided surgery systems (e.g., Stryker's SPY-PHI, Zeiss' INFRARED 800), radiofrequency-based devices (e.g., Dune Medical's MarginProbe), and advanced pathology techniques (e.g., intraoperative MRI, frozen section). Lumicell's differentiation lies in its real-time, cellular-level detection specifically designed for the post-excision cavity, a unique approach to the margin problem.